SEC For	m 4 FORM 4	4 U	ΝΙΤ	ED STAT	ES	SEC	URIT	IES	S ANI	DE	ХСНА	NGE	СОМ	IMIS	SION	N			
							Was	shingto	on, D.C.	. 205	649							ROV	'AL
to Sect	this box if no lo ion 16. Form 4		T OF CHANGES IN BENEFICIAL OWNE									ΗP	Estima	Number: ated average I					
	ions may contir tion 1(b).	lue. See		Filed							ies Exchar mpany Act					hours	per response:		0.5
1. Name and Address of Reporting Person <sup>*</sup> TREACE JAMES T					TR	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>TREACE MEDICAL CONCEPTS, INC.</u> [ TMCI ]									5. Relationship of Reporting Person(s) to Issu (Check all applicable) X Director 10% Own				
(Last) (First) (Middle)						-									Officer (give title Other (specify below) below)				
C/O TREACE MEDICAL CONCEPTS, INC. 203 FORT WADE ROAD, SUITE 150						3. Date of Earliest Transaction (Month/Day/Year) 12/28/2021													
(Street) PONTE FL 32081 VEDRA				1	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								ð. Indiv ₋ine) X	,				
(City)	(Sta	ate) (2	Zip)																
		Table	- I - I	Non-Deriva	tive	Secur	ities A	Acqu	iired,	Dis	posed o	of, or I	Benefic	ially	Owne	ed			
Date				2. Transaction Date (Month/Day/Ye	e E nth/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			Benefic Owned		ties cially Following	6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership
								Cod	le V	A	mount	(A) or (D)	Price			ed ction(s) 3 and 4)	(Instr. 4)		nstr. 4)
Common Stock				12/28/202	12/28/2021				L)		1,563	D	\$16.88	21 <sup>(3)</sup>	2		I	G	y J&A Froup LC <sup>(2)</sup>
Common Stock														1,0	06,183	Ι		y pouse	
Common Stock															1,4	61,441	D		
		Ta	ble	II - Derivati (e.g., pu											Owned	1			
1. Title of Derivative Security (Instr. 3) 2. 3. Transacti Date (Month/Day Derivative Security			3A. Deemed Execution Date, if any (Month/Day/Year)		Code	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date E Expiratio Month/E	on Da		Amo Secu Unde Deriv	rity (Instr. I 4)	Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y Direct ( or Indir (I) (Inst	hip D) ect	11. Nature of Indirec Beneficial Ownershi (Instr. 4)
													Amount or Number						

Explanation of Responses:

1. Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

2. James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$16.59 to \$17.39 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Date

Exercisable

Expiration Date

> /s/ Lisa Taylor as Attorney-infact for James T. Treace 12/30/2021

of Shares

Title

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

(A) (D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.